In fact, at least four drug approvals further strengthened this link: (1) the PDE5 inhibitors for erectile dysfunction and pulmonary arterial hypertension (PAH); (2) the first sGC stimulator in class, riociguat, in pulmonary arterial hypertension; (3) more recently the neprylisin inhibitor sacubitril combined with valsartan as well as (4) the sGC stimulator vericiguat in chronic heart failure (HF). This evidence concerns the gene SGCB and erectile dysfunction.